基于循环血微小RNA预测心脏再同步化治疗疗效

doi:10.3969/j.issn.1007-2861.2016.04.019

上海大学学报(自然科学版) ›› 2016, Vol. 22 ›› Issue (3): 265-269.doi: 10.3969/j.issn.1007-2861.2016.04.019

基于循环血微小RNA预测心脏再同步化治疗疗效

王菲, Saumya Das

哈佛医学院附属麻省总院心脏内科, 波士顿02215, MA, 美国

收稿日期:2016-06-13 出版日期:2016-06-30 发布日期:2016-06-30
通讯作者: Saumya Das(1969—), 男, 教授, 博士, 研究方向为心力衰竭. E-mail: sdas@mgh.harvard.edu
作者简介:Saumya Das(1969—), 男, 教授, 博士, 研究方向为心力衰竭. E-mail: sdas@mgh.harvard.edu

Circulating miRNAs predict response to cardiac resynchronization therapy

WANG Fei, Saumya Das

Cardiovascular Division, Massachusetts General Hospital of Harvard Medical School

Received:2016-06-13 Online:2016-06-30 Published:2016-06-30
Supported by:
National Institutes of Health (NCATS UH3 TR000901)

摘要/Abstract

摘要：

心力衰竭是一类严重危害人类健康的重大疾病, 心脏再同步化是一种治疗心室收缩不同步的心力衰竭患者的疗法, 但并不是所有的患者都可以获益. 因此, 发掘可以预测心脏再同步化治疗反应性的生物标记物具有重大意义. 微小RNA 可以稳定地存在于循环血中, 反映各种疾病状态, 而本研究组的研究发现通过循环血微小RNA-30d 的高表达可以预测心脏再同步化治疗的反应性, 具有一定的应用前景.

关键词: 微小RNA , 生物标记物, 心脏再同步化治疗

Abstract:

Heart failure (HF) is one of the most common syndrome seriously harmful to human health. Cardiac resynchronization therapy (CRT) is an exciting recent advancement for HF patient by targeting ventricular systolic dyssynchrony, but it has been proved that CRT cannot achieve hemodynamic or clinical benefit for all patients. It is very essential to find out biomarkers for predicting responsive patients. Circulating extracellular microRNAs(miRNAs) have emerged as novel biomarkers for many diseases. Recent study indicated that a high level of circulating miR-30d could predict response to CRT, which may have bright prospects in future research and application.

Key words: biomarker, microRNAs , cardiac resynchronization therapy

王菲, Saumya Das. 基于循环血微小RNA预测心脏再同步化治疗疗效[J]. 上海大学学报(自然科学版), 2016, 22(3): 265-269.

WANG Fei, Saumya Das. Circulating miRNAs predict response to cardiac resynchronization therapy[J]. Journal of Shanghai University（Natural Science Edition）, 2016, 22(3): 265-269.

参考文献

[1] Writing G M, Mozaffarian D, Benjamin E J, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association [J]. Circulation, 2016, 133(4): e38-e60.
[2] DeVore A D, Hammill B G, Sharma P P, et al. In-hospital worsening heart failure and associations with mortality, readmission, and healthcare utilization [J]. Journal of the American
Heart Association, 2014, DOI: 10.1161/JAHA.114.001088.
[3] Jaffe M L, Morin D P. Cardiac resynchronization therapy: history, present, status, and future directions [J]. The Ochsner Journal, 2014, 14: 596-607.
[4] Shenkman H J, Pampati V, Khandelwal A K, et al. Congestive heart failure and QRS duration: establishing prognosis study [J]. Chest, 2002, 122(2): 528-534.
[5] Cazeau S, Ritter P, Bakdach S, et al. Four chamber pacing in dilated cardiomyopathy [J]. Pacing and Clinical Electrophysiology: PACE, 1994, 17(11Pt2): 1974-1979.
[6] Kass D A, Chen C H, Curry C, et al. Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay [J]. Circulation, 1999, 99(12): 1567-1573.
[7] Auricchio A, Stellbrink C, Block M, et al. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure [J]. Circulation, 1999, 99(23): 2993-3001.
[8] Bax J J, Gorcsan J. Echocardiography and noninvasive imaging in cardiac resynchronization therapy: results of the PROSPECT (Predictors of Response to Cardiac Resynchronization Therapy) study in perspective [J]. Journal of the American College of Cardiology, 2009, 53(21): 1933-1943.
[9] Birnie D H, Tang A S. The problem of non-response to cardiac resynchronization therapy [J]. Current Opinion in Cardiology, 2006, 21(1): 20-26.
[10] Kirk J A, Kass D A. Electromechanical dyssynchrony and resynchronization of the failing heart [J]. Circulation Research, 2013, 113(6): 765-776.
[11] Yu C M, Sanderson J E, Gorcsan J. Echocardiography, dyssynchrony, and the response to cardiac resynchronization therapy [J]. European Heart Journal, 2010, 31(19): 2326-2337.

[12] Tanaka H, Nesser H J, Buck T, et al. Dyssynchrony by speckle-tracking echocardiography and response to cardiac resynchronization therapy: results of the Speckle Tracking and Resynchronization (STAR) study [J]. European Heart Journal, 2010, 31(14): 1690-1700.
[13] Chung E S, Leon A R, Tavazzi L, et al. Results of the predictors of response to CRT (PROSPECT) trial [J]. Circulation, 2008, 117(20): 2608-2616.
[14] Ono K, Kuwabara Y, Han J. MicroRNAs and cardiovascular diseases [J]. The FEBS Journal, 2011, 278(10): 1619-1633.
[15] Xiao J. MicroRNA therapeutics [J]. Mini Reviews in Medicinal Chemistry, 2015, 15(6): 440.
[16] Zhou L, Zang G, Zhang G, et al. MicroRNA and mRNA signatures in ischemia reperfusion injury in heart transplantation [J]. PLoS One, 2013, 8(11): e79805.
[17] Mendell J T, Olson E N. MicroRNAs in stress signaling and human disease [J]. Cell, 2012, 148(6): 1172-1187.
[18] Marfella R, Di Filippo C, Potenza N, et al. Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders [J].
European Journal of Heart Failure, 2013, 15(11): 1277-1288.
[19] Melman Y F, Shah R, Danielson K, et al. Circulating microRNA-30d is associated with response to cardiac resynchronization therapy in heart failure and regulates cardiomyocyte apoptosis: a translational pilot study [J]. Circulation, 2015, 131(25): 2202-2216.

基于循环血微小RNA预测心脏再同步化治疗疗效

Circulating miRNAs predict response to cardiac resynchronization therapy

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

本文评价

[1]	高峰1,2, 陈静海1,2. 非编码RNA调控心脏重构与再生[J]. 上海大学学报(自然科学版), 2016, 22(3): 302-309.
[2]	王建勋1, 高金宁1, 丁巍2. 非编码RNA与心肌重构[J]. 上海大学学报(自然科学版), 2016, 22(3): 310-317.